Company Overview
SAB Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to developing human polyclonal immunotherapeutic antibodies designed to treat immune system disorders and infectious diseases within the United States. This operational focus places the company squarely within the Healthcare sector, specifically the Biotechnology industry, where it pursues the advancement of potentially disease-modifying therapeutics through its lead product candidate, SAB-142. The organization employs a workforce of 86 individuals and maintains a market capitalization of $268.45M, reflecting its valuation as a publicly traded entity with significant but limited scale relative to large-cap pharmaceutical peers. The combination of a $268.45M market cap and N/A annual revenue indicates that the company is in a pre-revenue or early commercialization phase, where its market value is derived primarily from the potential of its pipeline assets rather than current sales performance, a common characteristic for clinical-stage biotechnology firms.
Financial Health
The company reports N/A for Revenue (TTM), a Net Income (TTM) of $4.26M, and an EBITDA of $-45,871,776, a structure that reveals a complex financial reality where accounting profits exist despite significant operating losses before interest, taxes, depreciation, and amortization. The presence of N/A revenue alongside a positive net income highlights a specific accounting dynamic where non-operating income or adjustments may be offsetting substantial operational deficits, necessitating a deep dive into the cost structure to understand how the company generates reported earnings without recorded sales. Free cash flow stands at $-21,992,690, which signifies a high consumption of cash reserves to fund ongoing research and development activities, thereby limiting the company's immediate financial flexibility for external expansion or acquisitions. All three margins—Gross Margin, Operating Margin, and Profit Margin—are reported at 0.0%, indicating that the company currently derives no gross profit from sales and operates at a break-even or loss level on both an operational and bottom-line basis before interest and taxes. On the liability side, the company holds $96.59M in cash against $5.95M in debt, resulting in a Debt to Equity ratio of 3.93, which suggests a leveraged balance sheet structure despite the substantial cash position often obscuring the true leverage risk in biotechnology contexts. The Current Ratio is 9.46, a figure that indicates an exceptionally strong short-term liquidity position, suggesting the company can easily meet its current obligations with its available liquid assets. Furthermore, the Return on Equity is 15.0% while the Return on Assets is -28.2%, a divergence that reveals management is generating significant returns on shareholder capital while simultaneously losing value on the total asset base, likely due to the high capital intensity of drug development relative to the asset base.
Valuation Assessment
The trailing P/E ratio is N/A and the Forward P/E is -11.58, a discrepancy that implies the market prices the stock based on future expectations rather than historical earnings, while the negative forward multiple reflects the company's projected inability to generate positive earnings in the near term. The Price to Book ratio is 1.20, indicating that the market values the company at a slight premium of 20% over its book value, which suggests investors are willing to pay more than the net asset value for the potential embedded in the clinical pipeline. Alternative valuation metrics such as Price to Sales (N/A) and EV/EBITDA (-2.27) provide further context, where the negative EV/EBITDA confirms that the enterprise value is lower than the EBITDA due to the significant negative earnings, a typical metric profile for loss-making biotech firms. Regarding price metrics, the 52-week high is $6.60 and the 52-week low is $1.00, placing the current trading range within a wide band that reflects the high volatility often associated with clinical-stage biopharmaceutical stocks. The Beta value is 0.61, which means the stock's price volatility is historically less than 40% of the broader market's movements, suggesting a lower systematic risk profile compared to large-cap equities despite the inherent risks of the biotechnology sector.
Growth & Income
The company reports N/A for Revenue Growth (YoY) and N/A for Earnings Growth (YoY), meaning there is no historical data to compare growth rates, which implies that any future earnings will need to grow from a very small or zero base to achieve meaningful expansion. Because the company does not pay dividends, the Dividend Yield is N/A and the Payout Ratio is 0.0%, which indicates that the company reinvests all available earnings and cash flow back into its operations and research pipeline rather than distributing income to shareholders. This reinvestment strategy is standard for clinical-stage biotechnology companies that prioritize funding the development of SAB-142 and other antibody candidates over returning capital to investors. In summary, the overall growth and income profile is characterized by a lack of current revenue growth metrics and zero dividend income, relying entirely on the potential future success of its development pipeline to generate value for stakeholders.